OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2-advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors

被引：0
|
作者：
Pistilli, Barbara
Bellet, Meritxell
Del Mastro, Lucia
McArthur, Heather L.
Meisel, Jane Lowe
Schmid, Peter
Sohn, Joohyuk
De Kermadec, Elisabeth
Wei, Rachel
Chan, Arlene
机构：
[1] Gustave Roussy, Villejuif, France
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Vall Hebron Inst Oncol, Barcelona, Spain
[4] IRCCS Osped Policlinico San Martino Genoa, Dept Clin Oncol, Genoa, Italy
[5] UT SouthWestern Med Ctr, Dallas, TX USA
[6] Emory Univ, Winship Canter Inst, Atlanta, GA USA
[7] Queen Mary Univ London, Barts Canc Inst, London, England
[8] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med, Seoul, South Korea
[9] Olema Oncol, San Francisco, CA USA
[10] Breast Canc Res Ctr WA, Nedlands, WA, Australia
[11] Curtin Univ, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1135
引用
收藏
页数：1
相关论文
共 50 条
  • [1] OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2-advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors
    Sohn, Joohyuk
    Pistilli, Barbara
    Bellet, Meritxell
    Del Mastro, Lucia
    McArthur, Heather L.
    Meisel, Jane Lowe
    Schmid, Peter
    Wei, Rachel
    Chan, Arlene
    de Kermadec, Elisabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS22 - TPS22
  • [2] OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of- care treatment for ER+, HER2-advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy
    Chan, Arlene
    Meisel, Jane
    Jhaveri, Komal
    Sohn, Joo Hyuk
    Bellet-Ezquerra, Meritxell
    Schroeder, Jason
    Shilkrut, Mark
    Pistilli, Barbara
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2-Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ditzel, Henrik J.
    CANCERS, 2021, 13 (21)
  • [4] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pretreated ER+/HER2- Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
  • [6] EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
    Aftimos, Philippe
    Bardia, Aditya
    Kaklamani, Virginia G.
    Lu, Janice
    Bihani, Teeru
    Jung, JungAh
    Anderson-Villaluz, Alfred T.
    Conlan, Maureen G.
    Cortes, Javier
    CANCER RESEARCH, 2020, 80 (04)
  • [7] EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 3 - 4
  • [8] EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
    Bardia, Aditya
    Bidard, Francois-Clement
    Neven, Patrick
    Streich, Guillermo
    Montero, Alberto J.
    Forget, Frederic
    Mouret-Reynier, Marie-Ange
    Sohn, Joo Hyuk
    Taylor, Donatienne
    Harnden, Kathleen K.
    Khong, Hung
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick
    Babu, Sunil
    Waters, Simon
    Deleu, Ines
    Garcia-Saenz, Jose Angel
    Bria, Emilio
    Cazzaniga, Marina Elena
    Aftimos, Philippe
    Cortes, Javier
    Tonini, Giulia
    Sahmoud, Tarek
    Habboubi, Nassir
    Grzegorzewski, Krzysztof
    Kaklamani, Virginia
    CANCER RESEARCH, 2023, 83 (05)
  • [9] A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2-early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
    Hamilton, Erika
    Loibl, Sibylle
    Niikura, Naoki
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Klinowska, Teresa
    Mayer, Ingrid A.
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Bachelot, Thomas
    CANCER RESEARCH, 2024, 84 (09)
  • [10] EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
    Bardia, A.
    Lu, J.
    Kaklamani, V.
    Jung, J.
    Anderson-Villaluz, A. T.
    Conlan, M. G.
    Bidard, F-C.
    Cortes, J.
    Aftimos, P. G.
    ANNALS OF ONCOLOGY, 2020, 31 : S80 - S80
12345